Literature DB >> 10676636

Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.

M Leverkus1, M Neumann, T Mengling, C T Rauch, E B Bröcker, P H Krammer, H Walczak.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to exert potent cytotoxic activity against many tumor cell lines but not against normal cells. It has been hypothesized that this difference in TRAIL sensitivity between normal and transformed cells might be due to the expression of the non-death-inducing TRAIL receptors (TRAIL-R) TRAIL-R3 and TRAIL-R4, presumably by competition for limited amounts of TRAIL. To assess the regulation of resistance versus sensitivity to TRAIL in primary as well as transformed keratinocytes, we examined TRAIL sensitivity, TRAIL receptor expression, and intracellular signaling events induced by TRAIL. Although TRAIL induced apoptosis in primary as well as transformed keratinocytes, a marked difference in sensitivity could be observed with primary keratinocytes (PK) being 5-fold less sensitive to TRAIL than transformed keratinocytes (TK). Yet both cell types exhibited similar TRAIL receptor surface expression, suggesting that expression of TRAIL-R3 and TRAIL-R4 may not be the main regulator of sensitivity to TRAIL. Biochemical analysis of the signaling events induced by TRAIL revealed that PK could be sensitized for TRAIL and, similarly, for TRAIL-R1- and TRAIL-R2-specific apoptosis by pretreatment of the cells with cycloheximide (CHX). This sensitization concomitantly resulted in processing of caspase-8, which did not occur in TRAIL-resistant PK. These data indicate that an early block of TRAIL-induced apoptosis was present in PK compared with TK or PK treated with CHX. Interestingly, cellular FLICE inhibitory protein (cFLIP) levels, high in PK and low in TK and several other squamous cell carcinoma cell lines, decreased rapidly after treatment of PK with CHX, correlating with the increase in TRAIL sensitivity and caspase-8 processing. Furthermore, ectopic expression of cFLIP long (cFLIP(L)) in TK by transfection with a cFLIP(L) expression vector resulted in resistance to TRAIL-mediated apoptosis of these cells. Thus, our results demonstrate that TRAIL sensitivity in PK is primarily regulated at the intracellular level rather than at the receptor level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676636

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).

Authors:  F Yang; P Shi; X Xi; S Yi; H Li; Q Sun; M Sun
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

Authors:  Rachel M Locklin; Ermanno Federici; Belen Espina; Philippa A Hulley; R Graham G Russell; Claire M Edwards
Journal:  Mol Cancer Ther       Date:  2007-12-07       Impact factor: 6.261

3.  TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation.

Authors:  V K Puduvalli; D Sampath; J M Bruner; J Nangia; R Xu; A P Kyritsis
Journal:  Apoptosis       Date:  2005-01       Impact factor: 4.677

4.  FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.

Authors:  Geng Zhang; Peijun He; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  Cancer Res       Date:  2013-06-25       Impact factor: 12.701

5.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

6.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

7.  Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.

Authors:  Kan Kondo; Seiji Yamasaki; Naoya Inoue; Tomoharu Sugie; Naoki Teratani; Takatsugu Kan; Yutaka Shimada
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

8.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

9.  Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.

Authors:  Peter Geserick; Mike Hupe; Maryline Moulin; W Wei-Lynn Wong; Maria Feoktistova; Beate Kellert; Harald Gollnick; John Silke; Martin Leverkus
Journal:  J Cell Biol       Date:  2009-12-28       Impact factor: 10.539

10.  Tumor-targeted delivery of biologically active TRAIL protein.

Authors:  H-Y Zhang; J-H Man; B Liang; T Zhou; C-H Wang; T Li; H-Y Li; W-H Li; B-F Jin; P-J Zhang; J Zhao; X Pan; K He; W-L Gong; X-M Zhang; A-L Li
Journal:  Cancer Gene Ther       Date:  2010-01-15       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.